Advertisement

Guillain-Barré-Syndrom (GBS) und chronische inflammatorische demyelinisierende Polyneuritis (CIDP)

  • P. Berlit

Zusammenfassung

Das Guillain-Barré-Syndrom (GBS) ist diejenige neuroimmunologische Erkrankung, bei der auch nach Kriterien der evidenzbasierten Medizin die gesicherte Indikation für den Einsatz von Immunglobulinen gegeben ist. In mehreren randomisierten und kontrollierten Studien wurde gezeigt, dass IVIg ebenso wie die Plasmaseparation in der Lage sind, den Gesamtverlauf und die Zeit einer etwaigen Respiratorpflicht signifikant zu verkürzen.

Bei der chronischen Variante des GBS, der chronischen inflammatorischen demyelinisierenden Polyneuritis (CIDP) wurden IVIg in mehreren unkontrollierten Studien eingesetzt mit Responderraten zwischen 60 und 80%. In wenigen randomisierten placebokontrollierten Studien waren die Ergebnisse nicht einheitlich. Ein Effekt von IVIg bei der CIDP ist insbesondere dann zu erwarten, wenn die Krankheitsdauer kürzer als ein Jahr ist, eine progrediente Symptomatik bis zum Beginn der Behandlung besteht, sowohl Arme als auch Beine von Paresen betroffen sind, eine Areflexie vorliegt und die motorische Nervenleitgeschwindigkeit des N. medianus verlangsamt ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Barnett MH, Pollard JD, Davies L, McLeod JG (1998) Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21:454–460PubMedCrossRefGoogle Scholar
  2. 2.
    Berlit P, Rakicky J (1992) The Miller Fisher Syndrome. Clin Neuro-ophthalmology 12:57–63Google Scholar
  3. 3.
    Berlit P, Weng Y (1996) Immunglobulinbehandlung der chronisch inflammatorischen demyelinisierenden Polyradikulitis. Nervenheilkunde 15:346–352Google Scholar
  4. 4.
    Bouchard C, Lacroix C, Planté V, Adams D, Chedru F, Guglielmi JM, Said G (1999) Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52:498–503PubMedGoogle Scholar
  5. 5.
    Choudhary PP, Hughes RAC (1995) Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QF Med 88:493–502Google Scholar
  6. 6.
    Dalakas MC (1999) Intravenous immunoglublin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22:1479–1497PubMedCrossRefGoogle Scholar
  7. 7.
    Dutch Guillain-Barré Syndrome Study Group (1994) Treatment of Guillain-Barré syndrome with high-dose immunoglobulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749–752CrossRefGoogle Scholar
  8. 8.
    Dyck PJ, O’Brien PC, Swanson C, Low P, Daube J (1985) Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 35:1173–1176PubMedGoogle Scholar
  9. 9.
    Dyck PJ, Litchy WJ, Kratz KM, Surez GA, Low PA, Pneda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845PubMedCrossRefGoogle Scholar
  10. 10.
    French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome (1987) Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 22:753–761CrossRefGoogle Scholar
  11. 11.
    Good JL, Chehrenama M, Mayer RF, Koski CL (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51:1735–1738PubMedGoogle Scholar
  12. 12.
    Guillain-Barré Study Group (1985) Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35:1096–1104Google Scholar
  13. 13.
    Guillain-Barré Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341:586–590Google Scholar
  14. 14.
    Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka KV, Swan AV, and the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1998) Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome. Ann Neurol 44:780–788PubMedCrossRefGoogle Scholar
  15. 15.
    Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC (1999) Randomized trial of interferon β-la in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53:57–61PubMedGoogle Scholar
  16. 16.
    Hahn AF (1998) Guillain-Barré syndrome. Lancet 352:635–641PubMedCrossRefGoogle Scholar
  17. 17.
    Hahn AF (1998) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 51:16–21Google Scholar
  18. 18.
    Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebocontrolled, cross-over study. Brain 119:1067–1077PubMedCrossRefGoogle Scholar
  19. 19.
    Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome — Part I. Muscle Nerve 18:137–153PubMedCrossRefGoogle Scholar
  20. 20.
    Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome — Part II. Muscle Nerve 18:154–164PubMedCrossRefGoogle Scholar
  21. 21.
    Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, McKhanna GM (1997) Patterns of clinical recovery in Guillain-Barré syndrome. Neurology 48:695–700PubMedGoogle Scholar
  22. 22.
    Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury AK, Griffin JW, McKhann GM (1999) Anti-GD la antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 45:168–173PubMedCrossRefGoogle Scholar
  23. 23.
    Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P (1992) Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 49:612–616PubMedCrossRefGoogle Scholar
  24. 24.
    Jacobs BC, Rothbarth PH, van der Meché FGA, Herbrink P, Schmitz PIM, de Klerk MA, van Doom PA (1998) The spectrum of antecedent infections in Guillain-Barré syndrome. Neurology 51:1110–1115PubMedGoogle Scholar
  25. 25.
    Kanra G, Uzon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H (1997) Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Pediatr Neurol 1:7–12CrossRefGoogle Scholar
  26. 26.
    Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T (1998) Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti GM1 antibody. Neurology 51:1656–1660PubMedGoogle Scholar
  27. 27.
    Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, Yuki N (2001) Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG Anti-GMl antibody. Muscle Nerve 24:54–58PubMedCrossRefGoogle Scholar
  28. 28.
    Molenaar DSM, van Doom PA, Vermeulen M (1997) Pulsed high dose dexametha-sone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 62:388–390PubMedCrossRefGoogle Scholar
  29. 29.
    Nevo V, Pestronk A, Kornberg AJ et al (1996) Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 47:98–102PubMedGoogle Scholar
  30. 30.
    Otten et al (1995) Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatry 59:359–361CrossRefGoogle Scholar
  31. 31.
    Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Lancet 349:225–230CrossRefGoogle Scholar
  32. 32.
    Qurshi AI, Choudhry MA, Akbar MS, Mohammed Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT (1999) Plasma exchange versus intravenous Immunglobulin treatment in myasthenic crisis. Neurology 52:629–632Google Scholar
  33. 33.
    Oh SJ, LaGanke C, Claussen GC (2001) Sensory Guillain-Barré syndrome. Neurology 56:82–86PubMedGoogle Scholar
  34. 34.
    Simmons Z, Wald JJ, Albers JW (1997) Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 20:1569–1575PubMedCrossRefGoogle Scholar
  35. 35.
    Sorensen PS (1999) Intravenous immunoglobulin treatment in neurologic disorders. Arch Neurol 56:1025–1032PubMedCrossRefGoogle Scholar
  36. 36.
    The French Cooperative Group on Plasma Exchange in Guillain-Barré-Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 41:298–306CrossRefGoogle Scholar
  37. 37.
    Trojaborg W (1998) Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Electroencephalography and clinical Neurophysiology 107:303–316PubMedCrossRefGoogle Scholar
  38. 38.
    van der Meché FGA, van Doom PA (1997) The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 20:136–147PubMedCrossRefGoogle Scholar
  39. 39.
    van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrom. N Engl J Med 326:1123–1129CrossRefGoogle Scholar
  40. 40.
    van Doom PA, Brand A, Strenger PFW, Meulstee J, Vermeulen M (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209–212Google Scholar
  41. 41.
    van Doom PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 48:217–220CrossRefGoogle Scholar
  42. 42.
    van Doom PA (1994) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 57:38–42CrossRefGoogle Scholar
  43. 43.
    Vermeulen M, van Doom PA, Brand A, Stengers PFW, Jennekens FGI, Busch HGM (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39PubMedCrossRefGoogle Scholar
  44. 44.
    Visser LH, Schmitz PIM, Meulstee J, van Doorn PA, van der Meché FGA (1999) Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 53:598–604PubMedGoogle Scholar
  45. 45.
    Visser LH, Van der Meche FG, Meulstee J, van Doorn PA (1998) Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatry 64:242–244PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2001

Authors and Affiliations

  • P. Berlit

There are no affiliations available

Personalised recommendations